Table 2 Perioperative characteristics, pathology, and oncologic outcome

Operation time (min)

499.4 ± 61.7

[464.0; 531.0]

389.9 ± 52.8

[364.5; 424.0]

464.4 ± 77.9

[420.5; 510.0]

Hospitalization time (days)

54.8 ± 52.6

[32.0; 49.0]

32.1 ± 14.5

[23.5; 33.0]

48.2 ± 45.7

[26.0; 49.0]

Chimney side

Left

17 (100.0%)

7 (87.5%)

24 (96.0%)

Right

0 (0.0%)

1 (12.5%)

1 (4.0%)

Pelvic lymph node dissection

Standard

1 (5.9%)

0 (0.0%)

1 (4.0%)

Extended

1 (5.9%)

8 (100.0%)

9 (36.0%)

Super-extended

15 (88.2%)

0 (0.0%)

15 (60.0%)

Pathologic T stage

 ≤ T2

11 (64.7%)

2 (25.0%)

13 (52.0%)

 ≥ T3

6 (35.3%)

6 (75.0%)

12 (48.0%)

Pathologic N stage

0

14 (82.4%)

5 (62.5%)

19 (76.0%)

1

1 (5.9%)

0 (0.0%)

1 (4.0%)

2

1 (5.9%)

1 (12.5%)

2 (8.0%)

3

1 (5.9%)

2 (25.0%)

3 (12.0%)

Removed lymph node count

32.6 ± 14.0

[23.0; 39.0]

28.5 ± 10.8

[21.5; 39.0]

31.3 ± 13.0

[22.0; 39.0]

Number of positive lymph node

0.3 ± 0.7

[0.0; 0.0]

1.4 ± 2.7

[0.0;2.0]

0.6 ± 1.6

[0.0;0.0]

Postoperative grade

G2

3 (18.8%)

0 (0.0%)

3 (12.5%)

G3

13 (81.2%)

8 (100.0%)

21 (87.5%)

Positive soft margin

0 (0.0%)

1 (12.5%)

1 (4.0%)

Lymphovascular invasion

3 (17.6%)

4 (50.0%)

7 (28.0%)

Adjuvant chemotherapy

1 (5.9%)

1 (12.5%)

2 (8.0%)

Recurrence

5 (29.4%)

4 (50.0%)

9 (36.0%)

Death

10 (58.8%)

4 (50.0%)

14 (56.0%)